Clinical Trials
10 trialsNCT05900986 2026-05-20
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Integro Theranostics
Phase 1/2 Completed
NCT07214532 2026-04-08
SIGNAL-ER 101
Natera, Inc.
Phase NA Recruiting
NCT02983071 2023-02-15
G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
G1 Therapeutics, Inc.
Phase 1/2 Unknown
NCT03455270 2022-12-15
G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer
G1 Therapeutics, Inc.
Phase 1 Completed
NCT03113825 2021-06-11
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Avelas Biosciences, Inc.
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT00044291 2015-07-31
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Completed
NCT00616135 2011-05-17
RESTORE-2
Cytori Therapeutics
Phase 4 Completed
NCT00267553 2007-09-10
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated
NCT00097344 2007-08-23
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated